Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $3.34 million which beat the analyst consensus estimate of $2.38 million by 40.34 percent. This is a 119.30 percent increase over sales of $1.52 million the same period last year.
Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $238
Morgan Stanley analyst Matthew Harrison maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $235 to $238.
